# A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Source: https://onco.cc/trials/nct03980054/  
OnCo record `nct03980054` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pyrotinib in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer is a phase 3 interventional study registered as NCT03980054 by Jiangsu HengRui Medicine Co., Ltd., with 2135 participants enrolled, started 2019-07-12 and due to reach its primary completion in 2027-06. Interventions recorded: Pyrotinib and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03980054
- Phase: 3
- Setting: A Phase III Study to Evaluate the Efficacy and Safety of Pyrotinib Versus Placebo in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 2135

## Sources

- ClinicalTrials.gov NCT03980054: https://clinicaltrials.gov/study/NCT03980054

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pyrotinib](https://onco.cc/drugs/pyrotinib/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct03980054.json